^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMX-001

    i
    Other names: BMX-001, BMX-HGG, manganese butoxyethyl pyridyl porphyrin, BMX 001, MnTnBuOE-2-PyP5+
    Associations

    News

    Trials
    Company:
    BioMimetix
    Drug class:
    Antioxidant
    Related drugs:
    Associations

    News

    Trials
    1m
    Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, NRG Oncology | Trial completion date: Sep 2026 --> Jan 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Sep 2026 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    cisplatin • BMX-001
    3ms
    BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=27, Not yet recruiting, BioMimetix JV, LLC
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    paclitaxel • BMX-001
    5ms
    Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (clinicaltrials.gov)
    P2, N=98, Not yet recruiting, NRG Oncology
    New P2 trial
    |
    cisplatin • BMX-001
    8ms
    Single-Cell Profiling Reveals Immune-Based Mechanisms Underlying Tumor Radiosensitization by a Novel Mn Porphyrin Clinical Candidate, MnTnBuOE-2-PyP5+ (BMX-001). (PubMed, Antioxidants (Basel))
    CellChat analysis showed that the number of cell-cell communications was the lowest in the MnBuOE/RT group. Our study is the first to provide evidence for the combined radiotherapy with a novel Mn porphyrin clinical candidate, BMX-001, from the perspective of each cell type within the tumor microenvironment.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    BMX-001
    8ms
    BMX-HGG: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, BioMimetix JV, LLC | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jan 2024 --> Aug 2023
    Trial completion date • Trial primary completion date
    |
    temozolomide • BMX-001
    8ms
    A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy (clinicaltrials.gov)
    P1/2, N=35, Terminated, BioMimetix JV, LLC | N=69 --> 35 | Trial completion date: Sep 2025 --> Apr 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Dec 2023; Cessation of grant funding
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    BMX-001
    10ms
    Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 (clinicaltrials.gov)
    P2, N=118, Recruiting, University of Nebraska | Trial completion date: Feb 2028 --> Jun 2029 | Trial primary completion date: Jan 2028 --> May 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    BMX-001
    11ms
    Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 (clinicaltrials.gov)
    P2, N=118, Recruiting, University of Nebraska | Trial completion date: Dec 2033 --> Feb 2028 | Trial primary completion date: May 2028 --> Jan 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    BMX-001
    11ms
    Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 (clinicaltrials.gov)
    P2, N=118, Recruiting, University of Nebraska | Trial completion date: Dec 2032 --> Dec 2033 | Trial primary completion date: May 2027 --> May 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    BMX-001
    12ms
    Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 (clinicaltrials.gov)
    P2, N=118, Recruiting, University of Nebraska | Trial completion date: Jun 2029 --> Dec 2032
    Trial completion date • Metastases
    |
    BMX-001
    12ms
    Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (clinicaltrials.gov)
    P1/2, N=24, Recruiting, University of Nebraska | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • mitomycin • BMX-001
    over1year
    The Redox-Active Manganese(III) Porphyrin, MnTnBuOE-2-PyP, Impairs the Migration and Invasion of Non-Small Cell Lung Cancer Cells, Either Alone or Combined with Cisplatin. (PubMed, Cancers (Basel))
    Manganese(III) porphyrin MnTnBuOE-2-PyP (MnBuOE, BMX-001) is a third-generation redox-active cationic substituted pyridylporphyrin-based drug with a good safety/toxicity profile that has been studied in several types of cancer. MnBuOE alone or combined with cisplatin downregulated MMP2, MMP9, VIM, EGFR and VEGFA and upregulated CDH1 in both cell lines. Overall, our data demonstrate the anti-metastatic potential of MnBuOE for the treatment of NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
    |
    EGFR H1975
    |
    cisplatin • BMX-001
    over2years
    A Redox-active Mn Porphyrin, MnTnBuOE-2-PyP, Synergizes with Carboplatin in Treatment of Chemoresistant Ovarian Cell Line. (PubMed, Oxid Med Cell Longev)
    We have employed a redox-active MnP (MnTnBuOE-2-PyP, Mn(III) meso-tetrakis (N-n-butoxyethylpyridinium-2-yl) porphyrin) frequently identified as superoxide dismutase mimic or BMX-001, to explore the redox status of normal ovarian cell in relation to two ovarian cancer cell lines: OV90 human serous ovarian cancer cell and chemotherapy-resistant OV90 cell (OVCD). It is significant to emphasize that MnP protects normal ovarian cell line, hTER7, against carboplatin toxicity. Our data demonstrate that the addition of MnP-based redox-active drugs may be used (via increasing excessively the oxidative stress of serous ovarian cancer cells) to improve cancer patients' chemotherapy outcomes, which develop resistance to platinum-based drugs.
    Preclinical • Journal
    |
    SOD2 (Superoxide Dismutase 2)
    |
    carboplatin • BMX-001
    over3years
    HO-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways. (PubMed, Oxid Med Cell Longev)
    The lead Mn porphyrins, namely, MnTE-2-PyP (BMX-010, AEOL10113), MnTnBuOE-2-PyP (BMX-001), and MnTnHex-2-PyP, were tested in numerous injuries of normal tissue and cellular and animal cancer models. The wealth of the data led to the progression of MnTnBuOE-2-PyP into four Phase II clinical trials on glioma, head and neck cancer, anal cancer, and multiple brain metastases, while MnTE-2-PyP is in Phase II clinical trial on atopic dermatitis and itch.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BMX-001